KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 103 filers reported holding KEROS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,489,552 | -18.9% | 360,400 | +2.2% | 3.74% | +10.3% |
| Q2 2023 | $14,169,477 | +39.4% | 352,650 | +48.2% | 3.39% | +11.3% |
| Q1 2023 | $10,162,600 | -11.1% | 238,000 | 0.0% | 3.04% | -23.4% |
| Q4 2022 | $11,428,760 | -5.4% | 238,000 | -25.9% | 3.97% | -20.4% |
| Q3 2022 | $12,087,000 | +58.5% | 321,300 | +16.4% | 4.99% | +45.2% |
| Q2 2022 | $7,626,000 | -47.2% | 276,000 | +3.9% | 3.44% | -23.4% |
| Q1 2022 | $14,451,000 | -7.1% | 265,750 | 0.0% | 4.49% | +36.1% |
| Q4 2021 | $15,549,000 | +11.5% | 265,750 | -24.6% | 3.30% | +26.6% |
| Q3 2021 | $13,945,000 | +39.7% | 352,500 | +50.0% | 2.60% | +57.1% |
| Q2 2021 | $9,980,000 | +3.0% | 235,000 | +49.2% | 1.66% | +16.4% |
| Q1 2021 | $9,694,000 | – | 157,500 | – | 1.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |